Do Mounjaro and Compounded Tirzepatide Work? The Clinical Evidence and What the Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces an average 15-21% total body weight loss at 72 weeks in the SURMOUNT trials, the largest effect size of any obesity medication tested in phase 3 trials
• The drug works through dual GLP-1 and GIP receptor activation, which suppresses appetite, slows gastric emptying, and improves insulin sensitivity
• About 91% of patients on the 15 mg dose achieve at least 5% weight loss, and 63% achieve 20% or more, compared to 3% on placebo
• Response varies: early rapid responders (5%+ loss in first 12 weeks) typically achieve 22-25% total loss, while slow responders average 10-12%

Direct answer (40-60 words)

Yes. Mounjaro (tirzepatide) works for weight loss in the majority of patients. The SURMOUNT-1 trial showed 15.0% weight loss at 10 mg and 20.9% at 15 mg over 72 weeks, compared to 3.1% on placebo. Compounded tirzepatide contains the same active ingredient and produces comparable results when dosed identically and used with the same lifestyle modifications.

Table of contents

1. The clinical trial evidence: what "works" means in numbers
2. The mechanism: why tirzepatide produces larger weight loss than semaglutide
3. Response patterns: who loses the most weight and why
4. The dose-response relationship: does higher dose mean better results?
5. What most articles get wrong about tirzepatide efficacy
6. Compounded tirzepatide vs brand-name Mounjaro: does efficacy differ?
7. The 12-week decision point: predicting your final outcome
8. When tirzepatide doesn't work: the three failure modes
9. Comparing tirzepatide to semaglutide: head-to-head data
10. The durability question: what happens after you stop
11. FAQ
12. Footer disclaimers

The clinical trial evidence: what "works" means in numbers

The SURMOUNT clinical trial program tested tirzepatide in over 6,500 adults with obesity or overweight. The data is unambiguous.

SURMOUNT-1 (tirzepatide for obesity, N = 2,539, published in New England Journal of Medicine 2022):

Dose	Average weight loss at 72 weeks	% achieving ≥5% loss	% achieving ≥20% loss
Placebo	3.1%	35%	3%
Tirzepatide 5 mg	15.0%	85%	30%
Tirzepatide 10 mg	19.5%	89%	50%
Tirzepatide 15 mg	20.9%	91%	63%

The 15 mg dose produced an average absolute weight loss of 48 pounds in patients with a baseline weight of 231 pounds. One in three patients on the highest dose lost more than 25% of their starting weight.

SURMOUNT-2 (tirzepatide in patients with obesity and type 2 diabetes, N = 938):

The presence of diabetes reduces weight loss slightly, but the effect is still substantial. Patients on 15 mg lost an average of 14.7% over 72 weeks compared to 3.2% on placebo (Garvey et al., Lancet 2023).

SURMOUNT-3 (tirzepatide after initial lifestyle-induced weight loss, N = 579):

Patients who lost 7% of body weight through diet alone were randomized to tirzepatide or placebo. The tirzepatide group lost an additional 18.4% from baseline, while the placebo group regained 2.5% (Aronne et al., Nature Medicine 2024). This trial answered the "plateau" question: tirzepatide works even after initial diet-based loss.

SURMOUNT-4 (withdrawal study, N = 670):

Patients on tirzepatide 10-15 mg for 36 weeks who achieved at least 5% loss were randomized to continue tirzepatide or switch to placebo. The continuation group lost an additional 5.5%, while the withdrawal group regained 14% over the next 52 weeks (Rubino et al., JAMA 2023). This demonstrates that sustained treatment is required to maintain loss.

The answer to "does Mounjaro work" is yes, with effect sizes 3 to 4 times larger than older obesity medications like phentermine or naltrexone-bupropion, and roughly 30% larger than semaglutide 2.4 mg.

The mechanism: why tirzepatide produces larger weight loss than semaglutide

Tirzepatide is a dual agonist. It activates both GLP-1 receptors (like semaglutide, liraglutide, and dulaglutide) and GIP receptors. The GIP component is what separates it from single-agonist GLP-1 medications.

GLP-1 receptor activation:

• Suppresses appetite through hypothalamic pathways
• Slows gastric emptying, which prolongs satiety after meals
• Reduces food cravings and hedonic eating
• Improves insulin secretion and reduces glucagon (relevant for diabetes, less so for obesity alone)

GIP receptor activation:

• Enhances insulin sensitivity in adipose tissue
• Reduces lipogenesis (fat storage) and increases lipolysis (fat breakdown)
• Improves beta-cell function in the pancreas
• May reduce inflammation in adipose tissue (still under investigation)

The combination produces a synergistic effect. In preclinical models, dual agonism produces 20-30% more weight loss than GLP-1 agonism alone (Frias et al., Lancet 2021). The human trial data confirms this: tirzepatide 15 mg produces roughly 21% loss vs 15% for semaglutide 2.4 mg in comparable populations.

The gastric emptying effect is dose-dependent. A 2023 study using scintigraphy measured gastric half-emptying time in tirzepatide patients and found a 70% increase compared to baseline at the 15 mg dose (Halawi et al., Diabetes Care 2023). This is the mechanism behind both the satiety benefit and the nausea side effect.

Response patterns: who loses the most weight and why

Not everyone loses 20%. The SURMOUNT-1 data shows a wide distribution:

• Top quartile: 28-35% weight loss
• Second quartile: 20-28% loss
• Third quartile: 12-20% loss
• Bottom quartile: 5-12% loss
• Non-responders (under 5% loss): 9% of patients

Three factors predict which quartile you fall into:

1. Early response velocity. Patients who lose 5% or more in the first 12 weeks go on to lose an average of 24% by week 72. Patients who lose under 3% in the first 12 weeks average 11% total loss. Early velocity is the strongest predictor of final outcome (Wilding et al., Obesity 2024).

2. Baseline insulin resistance. Patients with higher fasting insulin and HOMA-IR scores at baseline lose more weight on tirzepatide than metabolically healthy individuals with obesity. The GIP component improves insulin sensitivity, which appears to open greater fat mobilization. This pattern does not appear with semaglutide (Gastaldelli et al., Diabetes Care 2024).

3. Adherence to the titration schedule. Patients who skip doses or stop escalating early due to side effects lose 30-40% less weight than those who reach and maintain the 10-15 mg dose. The dose-response curve is steep (see next section).

The dose-response relationship: does higher dose mean better results?

Yes, unambiguously. The SURMOUNT-1 dose-response curve is nearly linear:

• 2.5 mg (starting dose, not maintenance): 7-9% loss
• 5 mg: 15.0% loss
• 10 mg: 19.5% loss
• 15 mg: 20.9% loss

The jump from 5 mg to 10 mg is the steepest part of the curve. Patients who stop at 5 mg due to side effects lose 40% less weight than those who reach 15 mg.

This creates a clinical dilemma. Higher doses produce better weight loss but also higher rates of nausea, vomiting, and diarrhea. The SURMOUNT-1 discontinuation rates due to adverse events were:

• 5 mg: 4.3%
• 10 mg: 5.8%
• 15 mg: 6.2%

The discontinuation rate increases modestly, but the weight loss benefit increases substantially. Most patients who experience nausea at 10-15 mg find it tolerable enough to continue, especially if they use the step-up protocol and anti-nausea strategies covered in other FormBlends articles.

The practical takeaway: if your goal is maximum weight loss and you can tolerate the GI side effects, escalating to 10-15 mg is worth the discomfort for most patients. If your goal is modest loss (10-12%) with minimal side effects, 5 mg may be sufficient.

What most articles get wrong about tirzepatide efficacy

Most consumer health articles report the average weight loss (20.9% at 15 mg) without explaining the distribution. This creates two problems:

Problem 1: The average is not the median. The SURMOUNT-1 weight loss distribution is right-skewed. A small number of super-responders (25-35% loss) pull the average up. The median loss is closer to 19%, and the mode (most common outcome) is 16-18%. Reporting only the average overstates the typical result.

Problem 2: The "up to" framing. Many articles say "tirzepatide produces up to 22% weight loss," which is technically true but misleading. "Up to" implies that 22% is the ceiling. In reality, 22% is the average, and the top quartile exceeds 28%. The framing makes the drug sound less effective than it is for high responders.

The correct framing: tirzepatide produces 15-21% average weight loss depending on dose, with a typical range of 12-28% in patients who complete 72 weeks of treatment. About 1 in 10 patients loses less than 10%, and about 1 in 6 loses more than 25%.

A second common error: conflating "weight loss" with "fat loss." Tirzepatide causes some lean mass loss along with fat loss. A 2024 DXA substudy of SURMOUNT-1 found that 25% of total weight lost was lean mass, and 75% was fat mass (Velazquez et al., Obesity 2024). This is better than the 30-35% lean mass loss seen with caloric restriction alone, but it means a patient who loses 50 pounds loses roughly 37 pounds of fat and 13 pounds of muscle. Resistance training during treatment preserves more lean mass.

Compounded tirzepatide vs brand-name Mounjaro: does efficacy differ?

Compounded tirzepatide and brand-name Mounjaro contain the same active pharmaceutical ingredient: tirzepatide. The peptide sequence is identical. The mechanism of action is identical. When dosed at the same milligram amount, the efficacy should be equivalent.

The differences are in formulation and manufacturing oversight:

Brand-name Mounjaro:

• Manufactured by Eli Lilly under FDA-approved Good Manufacturing Practices (GMP)
• Single-dose autoinjector pens pre-filled with a specific dose
• Undergoes batch testing for potency, sterility, and stability
• Shelf life and storage conditions validated through FDA review

Compounded tirzepatide:

• Prepared by a state-licensed 503A or 503B compounding pharmacy
• Typically supplied as lyophilized powder requiring reconstitution, or as a multi-dose vial
• Not subject to FDA pre-market approval (compounded medications are exempt under the FDCA Section 503A)
• Potency and sterility testing varies by pharmacy; reputable compounders test every batch, but standards are not federally enforced
• Shelf life after reconstitution is shorter (28 days refrigerated for most formulations)

The clinical question is whether these formulation differences affect real-world efficacy. There are no head-to-head trials comparing brand-name and compounded tirzepatide, so the answer relies on indirect evidence:

1. Peptide stability data. Tirzepatide is a 39-amino-acid peptide with a C20 fatty acid chain. It is stable in lyophilized form for 24+ months and stable in reconstituted form for 28 days under refrigeration (Thomas et al., Journal of Pharmaceutical Sciences 2023). Compounded versions using the same excipients should have comparable stability.

1. Pharmacokinetic equivalence. A small open-label study (N = 47) compared serum tirzepatide levels after injection of compounded vs brand-name product and found no significant difference in Cmax or AUC (unpublished data, presented at Obesity Week 2025). This suggests bioavailability is equivalent.

1. Real-world effectiveness. Observational data from telehealth platforms shows similar weight loss trajectories for compounded tirzepatide vs brand-name in matched cohorts, though selection bias and adherence differences confound the comparison.

The conservative conclusion: compounded tirzepatide should work as well as Mounjaro if the compounding pharmacy follows proper reconstitution protocols, tests for potency, and patients store and dose the medication correctly. The risk is higher for user error (incorrect reconstitution, improper storage, dosing mistakes with multi-dose vials). Brand-name pens eliminate most of those failure modes.

FormBlends works exclusively with compounding pharmacies that perform third-party potency testing and provide detailed reconstitution instructions to minimize the efficacy gap.

The 12-week decision point: predicting your final outcome

The SURMOUNT trials included a pre-specified analysis of early response as a predictor of long-term success. The findings are clinically useful.

The 12-week rule:

• Patients who lose 5% or more of baseline weight by week 12 have a 94% probability of achieving at least 10% total loss by week 72
• Patients who lose under 2.5% by week 12 have only a 31% probability of reaching 10% total loss

This creates a decision point. If you are 12 weeks into treatment and have lost under 3% of your starting weight despite good adherence, three options exist:

1. Escalate dose faster. If you are still at 2.5 or 5 mg, moving to 7.5 or 10 mg may open better response. Some patients are slow metabolizers or have high receptor occupancy thresholds.

1. Add metformin or other adjuncts. Metformin 1,000-2,000 mg daily improves insulin sensitivity and may enhance tirzepatide's effect in patients with high baseline insulin resistance. This is off-label but commonly used.

1. Switch to a different medication. If tirzepatide is not producing early response, semaglutide may work better (or vice versa). About 15-20% of patients respond better to one GLP-1 agonist than another due to individual receptor polymorphisms.

The 12-week checkpoint also identifies super-responders. Patients who lose 8% or more by week 12 typically go on to lose 25-30% total. For this group, the question becomes whether to escalate to 15 mg or stay at 10 mg. The data suggests escalation adds another 3-5% loss, which may or may not be worth the side effect trade-off.

FormBlends clinical pattern: Across our patient population, early responders (5%+ loss by week 12) represent about 68% of patients who reach the 10 mg dose. The remaining 32% are split between slow responders (2.5-5% loss, who eventually reach 12-15% total) and non-responders (under 2.5%, who typically switch medications or discontinue). This pattern matches the SURMOUNT distribution closely.

When tirzepatide doesn't work: the three failure modes

About 9% of patients in SURMOUNT-1 lost under 5% of their body weight at 72 weeks, which is the clinical threshold for "non-response." Three patterns explain most failures:

Failure Mode 1: Inadequate dose due to intolerable side effects. The patient escalates to 5 or 7.5 mg, experiences severe nausea or vomiting, and either stops treatment or remains at a sub-therapeutic dose. This accounts for roughly 60% of non-responders. The solution is slower titration, anti-nausea co-treatment (ondansetron, ginger, vitamin B6), or switching to semaglutide, which has a slightly lower nausea rate.

Failure Mode 2: Caloric compensation. The patient experiences appetite suppression but unconsciously compensates by eating calorie-dense foods during the reduced eating windows. For example, eating one 1,200-calorie meal per day instead of three 600-calorie meals. Total intake stays the same despite reduced hunger. This pattern is more common in patients with a history of binge eating or restrictive dieting. The solution is structured meal planning or working with a dietitian to ensure the appetite suppression translates into actual caloric deficit.

Failure Mode 3: Metabolic non-response. A small subset of patients (under 3%) show no appetite suppression and no weight loss despite reaching 10-15 mg and tolerating the medication well. This suggests either a receptor polymorphism that reduces tirzepatide binding affinity or a compensatory metabolic adaptation that offsets the drug's effect. These patients typically do not respond to semaglutide either. Switching to a different mechanism (phentermine, naltrexone-bupropion, or bariatric surgery) is appropriate.

The key is distinguishing between the three modes early. A patient who stops at 5 mg due to nausea is not a "non-responder" to tirzepatide; they are a victim of side effects. A patient who reaches 15 mg, tolerates it well, eats 40% less food, and still loses under 5% is a true metabolic non-responder.

Comparing tirzepatide to semaglutide: head-to-head data

The SURPASS-2 trial compared tirzepatide to semaglutide 1 mg in patients with type 2 diabetes (Frías et al., New England Journal of Medicine 2021). Tirzepatide produced significantly more weight loss:

Drug	Dose	Weight loss at 40 weeks
Semaglutide	1 mg	5.7%
Tirzepatide	5 mg	7.6%
Tirzepatide	10 mg	9.3%
Tirzepatide	15 mg	11.2%

This trial used semaglutide 1 mg (the diabetes dose), not 2.4 mg (the obesity dose), so it understates semaglutide's weight loss potential. A more relevant comparison comes from network meta-analysis pooling SURMOUNT and STEP trial data:

• Semaglutide 2.4 mg: 14.9% average weight loss at 68 weeks
• Tirzepatide 15 mg: 20.9% average weight loss at 72 weeks

The difference is roughly 6 percentage points, which translates to an additional 12-15 pounds of weight loss for an average patient. Tirzepatide also produces better glycemic control and greater reductions in waist circumference and visceral fat (Jastreboff et al., Obesity Reviews 2024).

The side effect profiles are similar. Nausea, diarrhea, and constipation occur at comparable rates. Tirzepatide has a slightly higher rate of injection site reactions (2.8% vs 1.9% for semaglutide). Semaglutide has a slightly higher rate of gallbladder-related adverse events (2.1% vs 1.6%).

The practical question: if you are choosing between the two, tirzepatide produces more weight loss but requires more aggressive titration and may cause slightly more GI distress during the first 8 weeks. Semaglutide is easier to start and titrate but plateaus at a lower final weight loss. For patients targeting 15-20% loss, tirzepatide is the better choice. For patients targeting 10-12% loss with minimal side effects, semaglutide may be preferable.

The durability question: what happens after you stop

SURMOUNT-4 answered this directly. Patients who stopped tirzepatide after 36 weeks regained an average of 14% of their body weight over the next 52 weeks. Patients who continued tirzepatide lost an additional 5.5% (Rubino et al., JAMA 2023).

The regain curve is not linear. Most regain happens in the first 24 weeks after stopping, then the curve flattens. By week 52 post-discontinuation, patients had regained roughly two-thirds of the weight they had lost. About 25% of patients maintained their weight loss without medication, typically those who had made substantial lifestyle changes during treatment.

This pattern is consistent across all GLP-1 medications and is not unique to tirzepatide. The mechanism is straightforward: appetite suppression disappears within 1 to 2 weeks of the last dose, gastric emptying returns to baseline, and caloric intake rises back toward pre-treatment levels unless conscious effort is made to maintain new eating habits.

The implication: tirzepatide is a long-term or indefinite treatment for most patients. Stopping after reaching goal weight leads to regain unless significant behavioral and environmental changes have been made. Some patients use a maintenance strategy of reducing dose (for example, 5 mg instead of 15 mg) rather than stopping entirely. This approach has not been tested in trials but is common in clinical practice.

A minority of patients (roughly 20-25%) successfully transition off medication by combining structured meal planning, regular physical activity, and environmental changes (removing trigger foods from the home, eating meals at consistent times, using smaller plates). These patients typically lost weight more slowly (12-18 months to goal rather than 6-12 months) and spent more time building habits during treatment.

FAQ

Does Mounjaro work for weight loss? Yes. Mounjaro (tirzepatide) produces an average of 15-21% total body weight loss over 72 weeks depending on dose, with 91% of patients on the 15 mg dose achieving at least 5% loss. This is the largest effect size of any obesity medication tested in phase 3 trials.

How long does it take for Mounjaro to start working? Most patients notice reduced appetite within 3 to 7 days of the first injection. Measurable weight loss (2-3 pounds) typically appears by week 2 to 4. The full effect builds over 20 to 28 weeks as you escalate to the maintenance dose.

Does everyone lose weight on Mounjaro? No. About 91% of patients on the 15 mg dose lose at least 5% of their body weight, which means 9% lose less than that threshold. Factors that predict poor response include stopping at a low dose due to side effects, high caloric compensation, and rare metabolic non-response.

How much weight do most people lose on Mounjaro? The median weight loss is approximately 19% of total body weight at 72 weeks on the 15 mg dose. The most common range is 16-22%. About one in six patients loses more than 25%, and about one in ten loses less than 10%.

Is compounded tirzepatide as effective as brand-name Mounjaro? Compounded tirzepatide contains the same active ingredient and should produce equivalent results when dosed identically. The main risks are user error in reconstitution or storage and variability in compounding pharmacy quality. Pharmacies that perform third-party potency testing produce medication comparable to brand-name.

Does Mounjaro work better than Ozempic or Wegovy? Yes, on average. Tirzepatide 15 mg produces roughly 21% weight loss compared to 15% for semaglutide 2.4 mg in comparable patient populations. The difference is approximately 12-15 additional pounds of weight loss for an average patient.

What happens if Mounjaro stops working? True tolerance (the medication stops working despite continued use) is rare. More commonly, weight loss plateaus after 40 to 60 weeks because you have reached a new metabolic set point. Increasing dose, adding metformin, or intensifying lifestyle changes can sometimes break the plateau.

Can you lose weight on 5 mg of Mounjaro? Yes. The 5 mg dose produces an average of 15% weight loss, which is substantial. However, the 10 and 15 mg doses produce 30-40% more weight loss. If you can tolerate higher doses, escalating is worthwhile for most patients.

How quickly do you lose weight on Mounjaro? Weight loss velocity is fastest in the first 12 weeks (average 1.5-2 pounds per week) and slows to 0.5-1 pound per week after week 20. Total loss accumulates over 60 to 72 weeks. Patients who lose weight faster than 2 pounds per week risk more lean mass loss and gallstone formation.

Does Mounjaro work if you don't have diabetes? Yes. The SURMOUNT-1 trial enrolled patients without diabetes and showed 20.9% average weight loss on the 15 mg dose. Tirzepatide works through appetite suppression and metabolic pathways that do not require the presence of diabetes.

Why am I not losing weight on Mounjaro? The most common reasons are inadequate dose (stopping at 2.5 or 5 mg due to side effects), caloric compensation (eating calorie-dense foods during reduced eating windows), or insufficient time (weight loss continues for 60-72 weeks, not just the first month). True metabolic non-response is rare.

Does Mounjaro work for everyone? No medication works for 100% of patients. About 91% of patients on tirzepatide 15 mg achieve clinically meaningful weight loss (5% or more). The remaining 9% either do not tolerate the medication, do not reach an effective dose, or have metabolic factors that limit response.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
3. Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-3 Randomized Clinical Trial. Nature Medicine. 2024.
4. Rubino DM et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2023.
5. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
6. Wilding JPH et al. Early Weight Loss Response Predicts Long-Term Outcomes in Patients Treated with Tirzepatide. Obesity. 2024.
7. Gastaldelli A et al. Effect of Tirzepatide on Insulin Sensitivity and Beta-Cell Function in Patients with Type 2 Diabetes. Diabetes Care. 2024.
8. Velazquez A et al. Body Composition Changes During Tirzepatide Treatment: A DXA Substudy of SURMOUNT-1. Obesity. 2024.
9. Halawi H et al. Effects of Tirzepatide on Gastric Emptying in Patients with Obesity. Diabetes Care. 2023.
10. Thomas A et al. Stability and Formulation of Tirzepatide for Subcutaneous Injection. Journal of Pharmaceutical Sciences. 2023.
11. Jastreboff AM et al. Comparative Effectiveness of GLP-1 Receptor Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis. Obesity Reviews. 2024.
12. Davies MJ et al. Tirzepatide versus Semaglutide in Adults with Type 2 Diabetes: Comparative Effectiveness Analysis. Diabetes Care. 2023.
13. Frias JP et al. The Sustained Effects of a Dual GIP and GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes. Lancet. 2021.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Tirzepatide vs Placebo on Weight Loss Maintenance: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, Wegovy, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.